S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma

Launched by YONSEI UNIVERSITY · Jul 10, 2015

Keywords

ClinConnect Summary

Though a significant decrease in its incidence over the last 70 years, gastric cancer remains a significant health problem worldwide. Despite the R0 resection and adjuvant chemotherapy, the prognosis for patients with locally advanced GC remains poor, with 5-year survival rate below 60%. Therefore, active strategy to improve survival outcome is ongoing in gastric cancer. Due to the nature of gastric surgery, postsurgical recovery can be avoided by the administration of systemic therapy and/or radiation prior to the surgical procedure. Furthermore, preoperative therapy has the theoretical ad...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed gastric cancer
• • Clinical stage : - Borrmann type IV
• • Large Borrmann type III (\>8cm)
• • Locally extensive nodal disease
• • No evidence of metastasis
• • Patients with tumor lesions which can be easily obtained fresh tumor tissue through repeated biopsies.
• • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
• • Age≥ 20 years old.
• • Performance status of Eastern Cooperative Oncology Group 0 to 2.
• • Adequate organ function.
• Exclusion Criteria:
• • 1. metastatic disease
• • 2. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ.
• • 3. Subjects with an uncontrolled major cardiovascular disease (including AMI within 12 months, unstable angina within 6 months, over NYHA class III congestive heart failure, congenital long QT syndrome, 2° or more AV Block and uncontrolled hypertension)
• • 4. Pregnant or lactating female
• • 5. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study